Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REAL8 study of once-weekly somapacitan versus daily Norditropin in children with short stature disorders
jRCT2031220263Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Trial of somapacitan and somatropin in Short stature in children born small for gestational age, Turner syndrome (TS), Noonan syndrome and 1 more (2 arms), sponsored by Novo Nordisk. Primary endpoint: Height velocity. Started Aug 2022; status: active, not recruiting.
02
Drugs
somapacitansomatropin
03
Conditions
Short stature in children born small for gestational ageTurner syndrome (TS)Noonan syndromeIdiopathic Short Stature (ISS)
Beyond the preview
Go deeper on jRCT2031220263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220263.